Kristine Domingo
Neurology · Minneapolis, MNNPI 1922426147
Payments from drug & device makers
What this record shows
This record is dominated by grants: $16,875 of the $17,359 with a category attached, or 97.2%. 4 manufacturers reported payments, led by Medtronic at 54.9% of the total. Reporting peaked in 2019 at $17,036 and has fallen 98.7% since, to $223 in 2024. Among neurology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $1335.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Boston Scientific$8K
- Merz Pharmaceuticals, LLC$85
- Abbott$15
Across 2 payments — averaging $10,540 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$21K
What the payments were for
- Grants$16,87597%
- Food & beverage$3302%
- Education$1551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 8 | $9,536 |
| Boston Scientific | 3 | $7,723 |
| Merz Pharmaceuticals, LLC | 1 | $85 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,359 in reported general payments places this provider in the 90th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 31 | $282,913 |
| IngrezzaValbenazine Tosylate | 24 | $197,557 |
| RytaryCarbidopa/Levodopa | 61 | $111,787 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 445 | $22,900 |
| NeuproRotigotine | 14 | $13,825 |
| Carbidopa | 16 | $9,869 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 177 | $5,929 |
| Entacapone | 47 | $4,904 |
| Gabapentin | 131 | $2,578 |
| Primidone | 85 | $2,167 |
| AmantadineAmantadine Hcl | 44 | $2,076 |
| Donepezil Hcl | 39 | $1,863 |
| Ropinirole Hcl | 39 | $1,775 |
| Rasagiline Mesylate | 12 | $1,545 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 58 | $1,300 |
Paid to pharmacies, not to this prescriber.
Other neurology in Minneapolis
- Jeffery AllenMinneapolis$1.1M
- Jerrold VitekMinneapolis$97K
- Leonardo Brito de AlmeidaMinneapolis$80K
- Kamaskshi LakshminarayanMinneapolis$64K
- Sanjay SinghMinneapolis$42K
- Elizabeth NeilMinneapolis$26K
- Allyson ConnorMinneapolis$23K
- Kelsey JensenMinneapolis$22K
- Javier Suarez OliverosMinneapolis$22K
- Ilo LeppikMinneapolis$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.